Cardinal Health shares set a record close after the company reported fourth-quarter fiscal 2026 results that beat adjusted earnings expectations despite a top-line revenue miss, according to LSEG data. Revenue for the quarter ending June 30 increased nearly 6% year over year to $63.67 billion, falling short of the $65.03 billion consensus estimate, while adjusted earnings per share reached $2.60, topping the $2.42 anticipated by analysts, driven by execution and increased operating efficiency in specialty pharmaceutical and direct-to-patient business segments.
Fourth-Quarter Financial Performance and Earnings Beat
For the fiscal fourth quarter, Cardinal Health reported revenue of $63.67 billion, marking a nearly 6% increase from the same period a year earlier, according to LSEG data cited in market reports. Although total sales missed the Wall Street consensus estimate of $65.03 billion, the company delivered an adjusted earnings per share of $2.60, outperforming the $2.42 analyst expectation, according to LSEG compilations.
The 18-cent earnings beat excludes a 31-cent per share benefit from tariff refunds paid by the U.S. government, following a Supreme Court decision to overturn the Trump administration’s duties. Following the report, Cardinal Health shares rose more than 1% on Tuesday, setting a fresh record close. The stock touched an intraday high of $258.30 during the session before retreating due to profit-taking, having previously reached an intraday peak of $244.01 on August 6 and an all-time closing high of $239.71 on July 7, according to market trading records.
Segment Breakdown: Pharmaceutical Solutions and Regulatory Headwinds
The Pharmaceutical and Specialty Solutions segment generated $58.85 billion in revenue during the quarter, representing a 6% year-over-year increase that came in slightly below expectations, according to company reports. Growth was driven by brand and specialty pharmaceutical sales from existing customers, alongside positive performance in the generics program. Segment profitability benefited from brand and specialty products, which carry favorable margins despite lower price points for generic drugs.
During the post-earnings investor call, CFO Aaron Alt noted that growth in GLP-1 drugs contributed to segment revenue. However, top-line performance faced pressure from lower drug prices resulting from Medicare negotiations authorized by the Inflation Reduction Act (IRA) of 2022, which took effect at the start of 2026. CEO Jason Hollar stated that the company operates on a volume-based, fee-for-service model that remains insulated from wholesale acquisition cost price caps, maintaining that Cardinal provides essential delivery services whose value does not change under pricing restrictions.
Global Medical and Emerging Business Results
In the Global Medical Products and Distribution segment, revenue totaled $3.13 billion, reflecting a slight year-over-year decline impacted by tariff refund recognitions, according to financial disclosures. The segment recorded $150 million in profit, which included a $100 million benefit from government tariff refunds. Excluding that refund, normalized segment profit stood at $50 million.
The Other segment, encompassing Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics, grew 7% year-over-year to $1.72 billion in revenue, missing Wall Street expectations. Despite trailing top-line estimates, the segment expanded its profit margin to 10.6%, significantly outpacing the roughly 1% margins found in Cardinal’s larger distribution segments. Growth in this unit was supported by at-Home Solutions—which includes Edgepark and Advanced Diabetes Supply Group providing direct-to-patient supplies—and OptiFreight Logistics shipping support services.
Fiscal 2027 Earnings Guidance and Cash Flow Projections
Cardinal Health issued full-year fiscal 2027 guidance projecting adjusted earnings growth of 13% to 15%, translating to an expected range of $12.40 to $12.60 per share, well ahead of the $12.04 consensus estimate compiled by LSEG. Management expects Pharmaceutical and Specialty Solutions segment revenue to increase 3% to 5% with 8% to 11% segment profit growth, while Global Medical Products and Distribution revenue is projected to rise 2% to 4% with segment profit between $200 million and $220 million. The Other segment is guided for 11% to 13% revenue growth and 15% to 18% profit growth. Free cash flow is anticipated to land between $3.5 billion and $4 billion, outpacing the $3.49 billion FactSet consensus, according to corporate disclosures.
Did you know? Cardinal Health’s “Other” segment achieves an operating margin of 10.6%, which is more than ten times higher than the profit margins typically recorded in its legacy pharmaceutical and medical distribution segments.
Frequently Asked Questions
What drove Cardinal Health’s earnings beat despite a revenue miss?
According to financial reports, adjusted earnings per share reached $2.60, beating the $2.42 consensus estimate due to strong operational efficiency, execution in high-margin specialty pharmaceuticals, and volume-based fee structures.
How did Medicare drug price negotiations impact Cardinal Health?
CFO Aaron Alt stated that lower drug prices resulting from Medicare negotiations under the Inflation Reduction Act created a top-line headwind that offset GLP-1 volume growth, though the company’s fee-for-service model insulated segment profits from direct price cap impacts.
What is Cardinal Health projecting for fiscal 2027?
Cardinal Health guided for full-year adjusted earnings growth of 13% to 15%, establishing an expected range of $12.40 to $12.60 per share, and projected free cash flow between $3.5 billion and $4 billion, according to company guidance.